Turning Tregs against cancer

Reprogramming immunosuppressive Tregs to inflammatory cells could enhance checkpoint inhibition therapy

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint inhibition therapy and the number of cancer patients

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers